Gamco Investors INC. ET AL boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 533,531 shares of the company’s stock after buying an additional 12,536 shares during the period. Gamco Investors INC. ET AL owned about 0.11% of Zoetis worth $33,282,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Fieldpoint Private Advisors Inc. boosted its stake in shares of Zoetis by 4.0% in the first quarter. Fieldpoint Private Advisors Inc. now owns 15,420 shares of the company’s stock worth $823,000 after buying an additional 600 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Zoetis by 3.6% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 12,512 shares of the company’s stock worth $624,000 after buying an additional 429 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Zoetis by 24.4% in the first quarter. Candriam Luxembourg S.C.A. now owns 47,336 shares of the company’s stock worth $2,526,000 after buying an additional 9,281 shares in the last quarter. Covenant Asset Management LLC purchased a new stake in shares of Zoetis during the first quarter worth $819,000. Finally, Retirement Systems of Alabama boosted its stake in shares of Zoetis by 1.6% in the first quarter. Retirement Systems of Alabama now owns 237,808 shares of the company’s stock worth $12,692,000 after buying an additional 3,745 shares in the last quarter. Institutional investors own 92.70% of the company’s stock.
Shares of Zoetis Inc. (NYSE:ZTS) opened at 60.75 on Friday. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85. The stock has a market cap of $29.71 billion, a PE ratio of 34.34 and a beta of 1.02. The stock’s 50 day moving average price is $61.95 and its 200 day moving average price is $58.24.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.53. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the business posted $0.49 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Gamco Investors INC. ET AL Increases Position in Zoetis Inc. (ZTS)” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/19/gamco-investors-inc-et-al-increases-position-in-zoetis-inc-zts.html.
A number of equities research analysts have weighed in on the company. Cowen and Company set a $70.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Monday, July 17th. Deutsche Bank AG reiterated a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Tuesday, June 20th. Hilliard Lyons assumed coverage on Zoetis in a research note on Tuesday, June 20th. They issued a “buy” rating and a $77.00 price objective for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $64.78.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
